Allogene Therapeutics: Q4 Earnings Snapshot
By AP News
Published - Mar 14, 2024, 04:19 PM ET
Last Updated - Mar 14, 2024, 04:19 PM EDT
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $85.8 million in its fourth quarter.
The South San Francisco, California-based company said it had a loss of 51 cents per share. Losses, adjusted for asset impairment costs, were 43 cents per share.
The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share.
The immuno-oncology company posted revenue of $21,000 in the period, meeting Street forecasts.
